Fulgent Genetics, Inc.
FLGT
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancerā¦ read more
Healthcare
Diagnostics & Research
9 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$18.56
Price-0.48%
-$0.09
1Y
Price
Market Cap
$527.116m
Small
Price/Earnings 3y Avg5y Avg
1,856x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-25.7%
EBITDA Margin-34.6%
Net Profit Margin-32.3%
Free Cash Flow Margin-25.7%
EBITDA Margin-34.6%
Net Profit Margin-32.3%
Free Cash Flow MarginRevenue
$323.932m
+0.4%
1y CAGR+4.1%
3y CAGR-10.3%
5y CAGREarnings
-$84.382m
-39.4%
1y CAGR-2.2%
3y CAGR-55.9%
5y CAGREPS
-$2.82
-43.1%
1y CAGR-2.6%
3y CAGR-57.4%
5y CAGRBook Value
$995.986m
$1.089b
Assets$93.237m
Liabilities$482k
DebtDebt to Assets
0.0%
-
Debt to EBITDAFree Cash Flow
-$103.787m
+16.4%
1y CAGR-343.4%
3y CAGR-282.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company